Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Portrazza (necitumumab) for the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Drug (Brand / Generic)

Portrazza / necitumumab

Company

Eli Lilly

Therapy Class

Recombinant human lgG1 monoclonal antibody

Current Indication

Recombinant human lgG1 monoclonal antibody

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top